Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
JPMorgan to hold a virtual conference » 04:55
01/14/21
01/14
04:55
01/14/21
04:55
ABMD

Abiomed

$323.77 /

-1.24 (-0.38%)

, AGIO

Agios Pharmaceuticals

$46.48 /

-0.06 (-0.13%)

, AHCO

AdaptHealth

$36.94 /

+0.165 (+0.45%)

, BCAB

BioAtla

$44.92 /

+3.54 (+8.55%)

, NXGN

NextGen Healthcare

$21.27 /

+0.79 (+3.86%)

, OLMA

Olema Oncology

$41.90 /

-0.07 (-0.17%)

, PCRX

Pacira

$73.50 /

+0.39 (+0.53%)

, BIIB

Biogen

$266.71 /

-0.81 (-0.30%)

, ESPR

Esperion

$26.94 /

-3.335 (-11.02%)

, EXEL

Exelixis

$24.38 /

-0.845 (-3.35%)

, HQY

HealthEquity

$75.73 /

-0.25 (-0.33%)

, MORF

Morphic Holding

$30.30 /

+0.29 (+0.97%)

, NNOX

Nano-X Imaging

$54.30 /

+2.66 (+5.15%)

, SRPT

Sarepta

$87.22 /

+0.03 (+0.03%)

, SHC

Sotera Health

$25.01 /

-0.19 (-0.75%)

, RVNC

Revance

$29.02 /

-0.45 (-1.53%)

, RUBY

Rubius Therapeutics

$8.89 /

-0.28 (-3.05%)

, ZYME

Zymeworks

$52.97 /

-0.87 (-1.62%)

39th Annual Healthcare…

39th Annual Healthcare Virtual Conference will be held on January 11-14.

ShowHide Related Items >><<
ZYME Zymeworks
$52.97 /

-0.87 (-1.62%)

SRPT Sarepta
$87.22 /

+0.03 (+0.03%)

SHC Sotera Health
$25.01 /

-0.19 (-0.75%)

RVNC Revance
$29.02 /

-0.45 (-1.53%)

RUBY Rubius Therapeutics
$8.89 /

-0.28 (-3.05%)

PCRX Pacira
$73.50 /

+0.39 (+0.53%)

NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

MORF Morphic Holding
$30.30 /

+0.29 (+0.97%)

HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

EXEL Exelixis
$24.38 /

-0.845 (-3.35%)

ESPR Esperion
$26.94 /

-3.335 (-11.02%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

AHCO AdaptHealth
$36.94 /

+0.165 (+0.45%)

AGIO Agios Pharmaceuticals
$46.48 /

-0.06 (-0.13%)

ABMD Abiomed
$323.77 /

-1.24 (-0.38%)

ABMD Abiomed
$323.77 /

-1.24 (-0.38%)

12/21/20 SVB Leerink
Abiomed price target raised to $320 from $280 at SVB Leerink
12/14/20 Piper Sandler
Abiomed gets approval for XR sheath, says Piper Sandler
10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
AGIO Agios Pharmaceuticals
$46.48 /

-0.06 (-0.13%)

12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/22/20 Barclays
Agios could enter 2022 with a third fewer shares, says Barclays
AHCO AdaptHealth
$36.94 /

+0.165 (+0.45%)

01/07/21 Canaccord
AdaptHealth price target raised to $50 from $39 at Canaccord
12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
BCAB BioAtla
$44.92 /

+3.54 (+8.55%)

01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
NXGN NextGen Healthcare
$21.27 /

+0.79 (+3.86%)

10/23/20 SVB Leerink
NextGen Healthcare price target raised to $14 from $12 at SVB Leerink
10/23/20 Piper Sandler
NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler
07/31/20 Piper Sandler
NextGen Healthcare price target raised to $23 from $17 at Piper Sandler
06/02/20 Deutsche Bank
NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank
OLMA Olema Oncology
$41.90 /

-0.07 (-0.17%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
PCRX Pacira
$73.50 /

+0.39 (+0.53%)

01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
BIIB Biogen
$266.71 /

-0.81 (-0.30%)

01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
ESPR Esperion
$26.94 /

-3.335 (-11.02%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
EXEL Exelixis
$24.38 /

-0.845 (-3.35%)

12/14/20 William Blair
Calithera risk/reward attractive into CANTATA readout, says William Blair
10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

01/06/21 BTIG
HealthEquity initiated with a Neutral at BTIG
01/06/21 Deutsche Bank
HealthEquity price target raised to $77 from $60 at Deutsche Bank
12/08/20 Cantor Fitzgerald
HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald
12/08/20 JPMorgan
HealthEquity price target raised to $72 from $61 at JPMorgan
MORF Morphic Holding
$30.30 /

+0.29 (+0.97%)

10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

09/15/20 Cantor Fitzgerald
Cantor reiterates $70 target on Nano-X after 'unfounded' short report
09/15/20 Cantor Fitzgerald
Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald
09/15/20 Oppenheimer
Nano-X Imaging initiated with a Perform at Oppenheimer
09/15/20 Berenberg
Nano-X Imaging initiated with a Buy at Berenberg
SRPT Sarepta
$87.22 /

+0.03 (+0.03%)

01/12/21 Citi
Sarepta downgraded to Neutral from Buy at Citi
01/11/21
Fly Intel: Top five analyst downgrades
01/11/21 UBS
Sarepta downgraded to Neutral on 'unexpected negative' results at UBS
01/11/21 UBS
Sarepta downgraded to Neutral from Buy at UBS
SHC Sotera Health
$25.01 /

-0.19 (-0.75%)

01/13/21 Baird
Sotera Health initiated with an Outperform at Baird
12/15/20 KeyBanc
Sotera Health initiated with an Overweight at KeyBanc
12/15/20 JPMorgan
Sotera Health initiated with an Overweight at JPMorgan
12/15/20 Jefferies
Sotera Health initiated with a Buy at Jefferies
RVNC Revance
$29.02 /

-0.45 (-1.53%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
RUBY Rubius Therapeutics
$8.89 /

-0.28 (-3.05%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
ZYME Zymeworks
$52.97 /

-0.87 (-1.62%)

01/12/21 SVB Leerink
Zymeworks price target raised to $66 from $45 at SVB Leerink
01/12/21 Wells Fargo
Zymeworks price target raised to $71 from $58 at Wells Fargo
09/29/20 JPMorgan
Zymeworks resumed with a Neutral at JPMorgan
08/06/20
Fly Intel: Top analyst initiations
ZYME Zymeworks
$52.97 /

-0.87 (-1.62%)

SRPT Sarepta
$87.22 /

+0.03 (+0.03%)

SHC Sotera Health
$25.01 /

-0.19 (-0.75%)

RVNC Revance
$29.02 /

-0.45 (-1.53%)

RUBY Rubius Therapeutics
$8.89 /

-0.28 (-3.05%)

PCRX Pacira
$73.50 /

+0.39 (+0.53%)

NXGN NextGen Healthcare
$21.27 /

+0.79 (+3.86%)

NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

MORF Morphic Holding
$30.30 /

+0.29 (+0.97%)

HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

EXEL Exelixis
$24.38 /

-0.845 (-3.35%)

ESPR Esperion
$26.94 /

-3.335 (-11.02%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

AHCO AdaptHealth
$36.94 /

+0.165 (+0.45%)

AGIO Agios Pharmaceuticals
$46.48 /

-0.06 (-0.13%)

ABMD Abiomed
$323.77 /

-1.24 (-0.38%)

  • 06
    Jan
  • 15
    Dec
  • 16
    Dec
  • 19
    Nov
  • 20
    Nov
  • 03
    Sep
  • 21
    Aug
  • 09
    Jul
  • 01
    Jul
  • 12
    Feb
  • 23
    Jan
NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

SRPT Sarepta
$87.22 /

+0.03 (+0.03%)

RVNC Revance
$29.02 /

-0.45 (-1.53%)

OLMA Olema Oncology
$41.90 /

-0.07 (-0.17%)

NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

ESPR Esperion
$26.94 /

-3.335 (-11.02%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

BCAB BioAtla
$44.92 /

+3.54 (+8.55%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

NNOX Nano-X Imaging
$54.30 /

+2.66 (+5.15%)

HQY HealthEquity
$75.73 /

-0.25 (-0.33%)

ESPR Esperion
$26.94 /

-3.335 (-11.02%)

BIIB Biogen
$266.71 /

-0.81 (-0.30%)

AHCO AdaptHealth
$36.94 /

+0.165 (+0.45%)

Conference/Events
JPMorgan to hold a virtual conference » 04:55
01/13/21
01/13
04:55
01/13/21
04:55
ABMD

Abiomed

$324.65 /

+0.28 (+0.09%)

, AGIO

Agios Pharmaceuticals

$46.54 /

-0.19 (-0.41%)

, AHCO

AdaptHealth

$36.78 /

-0.405 (-1.09%)

, BCAB

BioAtla

$41.38 /

+1.38 (+3.45%)

, NXGN

NextGen Healthcare

$20.50 /

+0.89 (+4.54%)

, OLMA

Olema Oncology

$41.97 /

+0.84 (+2.04%)

, PCRX

Pacira

$73.11 /

+1.46 (+2.04%)

, BIIB

Biogen

$267.44 /

-0.13 (-0.05%)

, ESPR

Esperion

$30.28 /

-1.01 (-3.23%)

, EXEL

Exelixis

$25.23 /

+1.1 (+4.56%)

, HQY

HealthEquity

$75.95 /

+1.83 (+2.47%)

, MORF

Morphic Holding

$30.12 /

+0.27 (+0.90%)

, NNOX

Nano-X Imaging

$51.61 /

+0.22 (+0.43%)

, SRPT

Sarepta

$87.32 /

-2.46 (-2.74%)

, SHC

Sotera Health

$25.20 /

-0.39 (-1.52%)

, RVNC

Revance

$29.47 /

+0.46 (+1.59%)

, RUBY

Rubius Therapeutics

$9.16 /

+0.12 (+1.33%)

, ZYME

Zymeworks

$53.99 /

-2.49 (-4.41%)

39th Annual Healthcare…

39th Annual Healthcare Virtual Conference will be held on January 11-14.

ShowHide Related Items >><<
ZYME Zymeworks
$53.99 /

-2.49 (-4.41%)

SRPT Sarepta
$87.32 /

-2.46 (-2.74%)

SHC Sotera Health
$25.20 /

-0.39 (-1.52%)

RVNC Revance
$29.47 /

+0.46 (+1.59%)

RUBY Rubius Therapeutics
$9.16 /

+0.12 (+1.33%)

PCRX Pacira
$73.11 /

+1.46 (+2.04%)

NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

MORF Morphic Holding
$30.12 /

+0.27 (+0.90%)

HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

EXEL Exelixis
$25.23 /

+1.1 (+4.56%)

ESPR Esperion
$30.28 /

-1.01 (-3.23%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

AHCO AdaptHealth
$36.78 /

-0.405 (-1.09%)

AGIO Agios Pharmaceuticals
$46.54 /

-0.19 (-0.41%)

ABMD Abiomed
$324.65 /

+0.28 (+0.09%)

ABMD Abiomed
$324.65 /

+0.28 (+0.09%)

12/21/20 SVB Leerink
Abiomed price target raised to $320 from $280 at SVB Leerink
12/14/20 Piper Sandler
Abiomed gets approval for XR sheath, says Piper Sandler
10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
AGIO Agios Pharmaceuticals
$46.54 /

-0.19 (-0.41%)

12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/22/20 Barclays
Agios could enter 2022 with a third fewer shares, says Barclays
AHCO AdaptHealth
$36.78 /

-0.405 (-1.09%)

01/07/21 Canaccord
AdaptHealth price target raised to $50 from $39 at Canaccord
12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
BCAB BioAtla
$41.38 /

+1.38 (+3.45%)

01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
NXGN NextGen Healthcare
$20.50 /

+0.89 (+4.54%)

10/23/20 SVB Leerink
NextGen Healthcare price target raised to $14 from $12 at SVB Leerink
10/23/20 Piper Sandler
NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler
07/31/20 Piper Sandler
NextGen Healthcare price target raised to $23 from $17 at Piper Sandler
06/02/20 Deutsche Bank
NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank
OLMA Olema Oncology
$41.97 /

+0.84 (+2.04%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
PCRX Pacira
$73.11 /

+1.46 (+2.04%)

01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
BIIB Biogen
$267.44 /

-0.13 (-0.05%)

01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
ESPR Esperion
$30.28 /

-1.01 (-3.23%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
EXEL Exelixis
$25.23 /

+1.1 (+4.56%)

12/14/20 William Blair
Calithera risk/reward attractive into CANTATA readout, says William Blair
10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

01/06/21 BTIG
HealthEquity initiated with a Neutral at BTIG
01/06/21 Deutsche Bank
HealthEquity price target raised to $77 from $60 at Deutsche Bank
12/08/20 Cantor Fitzgerald
HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald
12/08/20 JPMorgan
HealthEquity price target raised to $72 from $61 at JPMorgan
MORF Morphic Holding
$30.12 /

+0.27 (+0.90%)

10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

09/15/20 Cantor Fitzgerald
Cantor reiterates $70 target on Nano-X after 'unfounded' short report
09/15/20 Cantor Fitzgerald
Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald
09/15/20 Oppenheimer
Nano-X Imaging initiated with a Perform at Oppenheimer
09/15/20 Berenberg
Nano-X Imaging initiated with a Buy at Berenberg
SRPT Sarepta
$87.32 /

-2.46 (-2.74%)

01/12/21 Citi
Sarepta downgraded to Neutral from Buy at Citi
01/11/21
Fly Intel: Top five analyst downgrades
01/11/21 UBS
Sarepta downgraded to Neutral on 'unexpected negative' results at UBS
01/11/21 UBS
Sarepta downgraded to Neutral from Buy at UBS
SHC Sotera Health
$25.20 /

-0.39 (-1.52%)

12/15/20 KeyBanc
Sotera Health initiated with an Overweight at KeyBanc
12/15/20 JPMorgan
Sotera Health initiated with an Overweight at JPMorgan
12/15/20 Jefferies
Sotera Health initiated with a Buy at Jefferies
12/15/20 Citi
Sotera Health initiated with a Buy at Citi
RVNC Revance
$29.47 /

+0.46 (+1.59%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
RUBY Rubius Therapeutics
$9.16 /

+0.12 (+1.33%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
ZYME Zymeworks
$53.99 /

-2.49 (-4.41%)

01/12/21 SVB Leerink
Zymeworks price target raised to $66 from $45 at SVB Leerink
01/12/21 Wells Fargo
Zymeworks price target raised to $71 from $58 at Wells Fargo
09/29/20 JPMorgan
Zymeworks resumed with a Neutral at JPMorgan
08/06/20
Fly Intel: Top analyst initiations
ZYME Zymeworks
$53.99 /

-2.49 (-4.41%)

SRPT Sarepta
$87.32 /

-2.46 (-2.74%)

SHC Sotera Health
$25.20 /

-0.39 (-1.52%)

RVNC Revance
$29.47 /

+0.46 (+1.59%)

RUBY Rubius Therapeutics
$9.16 /

+0.12 (+1.33%)

PCRX Pacira
$73.11 /

+1.46 (+2.04%)

NXGN NextGen Healthcare
$20.50 /

+0.89 (+4.54%)

NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

MORF Morphic Holding
$30.12 /

+0.27 (+0.90%)

HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

EXEL Exelixis
$25.23 /

+1.1 (+4.56%)

ESPR Esperion
$30.28 /

-1.01 (-3.23%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

AHCO AdaptHealth
$36.78 /

-0.405 (-1.09%)

AGIO Agios Pharmaceuticals
$46.54 /

-0.19 (-0.41%)

ABMD Abiomed
$324.65 /

+0.28 (+0.09%)

  • 06
    Jan
  • 15
    Dec
  • 16
    Dec
  • 19
    Nov
  • 20
    Nov
  • 03
    Sep
  • 21
    Aug
  • 09
    Jul
  • 01
    Jul
  • 12
    Feb
  • 23
    Jan
NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

SRPT Sarepta
$87.32 /

-2.46 (-2.74%)

RVNC Revance
$29.47 /

+0.46 (+1.59%)

OLMA Olema Oncology
$41.97 /

+0.84 (+2.04%)

NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

ESPR Esperion
$30.28 /

-1.01 (-3.23%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

BCAB BioAtla
$41.38 /

+1.38 (+3.45%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

NNOX Nano-X Imaging
$51.61 /

+0.22 (+0.43%)

HQY HealthEquity
$75.95 /

+1.83 (+2.47%)

ESPR Esperion
$30.28 /

-1.01 (-3.23%)

BIIB Biogen
$267.44 /

-0.13 (-0.05%)

AHCO AdaptHealth
$36.78 /

-0.405 (-1.09%)

Conference/Events
JPMorgan to hold a virtual conference » 04:55
01/12/21
01/12
04:55
01/12/21
04:55
ABMD

Abiomed

$324.31 /

+0.31 (+0.10%)

, AGIO

Agios Pharmaceuticals

$46.71 /

+0.81 (+1.76%)

, AHCO

AdaptHealth

$37.18 /

-1.06 (-2.77%)

, BCAB

BioAtla

$40.00 /

+1.79 (+4.68%)

, NXGN

NextGen Healthcare

$19.60 /

-0.26 (-1.31%)

, OLMA

Olema Oncology

$41.65 /

-0.84 (-1.98%)

, PCRX

Pacira

$71.65 /

+1.58 (+2.25%)

, BIIB

Biogen

$267.53 /

+15.17 (+6.01%)

, ESPR

Esperion

$31.29 /

+0.25 (+0.81%)

, EXEL

Exelixis

$24.13 /

+1.3 (+5.69%)

, HQY

HealthEquity

$74.12 /

-1.03 (-1.37%)

, MORF

Morphic Holding

$29.83 /

-0.64 (-2.10%)

, NNOX

Nano-X Imaging

$51.39 /

-1.625 (-3.07%)

, SRPT

Sarepta

$89.78 /

+7.48 (+9.09%)

, SHC

Sotera Health

$25.59 /

+0.59 (+2.36%)

, RVNC

Revance

$29.00 /

-0.41 (-1.39%)

, RUBY

Rubius Therapeutics

$9.03 /

-0.47 (-4.95%)

, ZYME

Zymeworks

$56.48 /

-0.45 (-0.79%)

39th Annual Healthcare…

39th Annual Healthcare Virtual Conference will be held on January 11-14.

ShowHide Related Items >><<
ZYME Zymeworks
$56.48 /

-0.45 (-0.79%)

SRPT Sarepta
$89.78 /

+7.48 (+9.09%)

SHC Sotera Health
$25.59 /

+0.59 (+2.36%)

RVNC Revance
$29.00 /

-0.41 (-1.39%)

RUBY Rubius Therapeutics
$9.03 /

-0.47 (-4.95%)

PCRX Pacira
$71.65 /

+1.58 (+2.25%)

NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

MORF Morphic Holding
$29.83 /

-0.64 (-2.10%)

HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

EXEL Exelixis
$24.13 /

+1.3 (+5.69%)

ESPR Esperion
$31.29 /

+0.25 (+0.81%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

AHCO AdaptHealth
$37.18 /

-1.06 (-2.77%)

AGIO Agios Pharmaceuticals
$46.71 /

+0.81 (+1.76%)

ABMD Abiomed
$324.31 /

+0.31 (+0.10%)

ABMD Abiomed
$324.31 /

+0.31 (+0.10%)

12/21/20 SVB Leerink
Abiomed price target raised to $320 from $280 at SVB Leerink
12/14/20 Piper Sandler
Abiomed gets approval for XR sheath, says Piper Sandler
10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
AGIO Agios Pharmaceuticals
$46.71 /

+0.81 (+1.76%)

12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/22/20 Barclays
Agios could enter 2022 with a third fewer shares, says Barclays
AHCO AdaptHealth
$37.18 /

-1.06 (-2.77%)

01/07/21 Canaccord
AdaptHealth price target raised to $50 from $39 at Canaccord
12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
BCAB BioAtla
$40.00 /

+1.79 (+4.68%)

01/11/21 JPMorgan
BioAtla initiated with an Overweight at JPMorgan
01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
NXGN NextGen Healthcare
$19.60 /

-0.26 (-1.31%)

10/23/20 SVB Leerink
NextGen Healthcare price target raised to $14 from $12 at SVB Leerink
10/23/20 Piper Sandler
NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler
07/31/20 Piper Sandler
NextGen Healthcare price target raised to $23 from $17 at Piper Sandler
06/02/20 Deutsche Bank
NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank
OLMA Olema Oncology
$41.65 /

-0.84 (-1.98%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
PCRX Pacira
$71.65 /

+1.58 (+2.25%)

01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
BIIB Biogen
$267.53 /

+15.17 (+6.01%)

01/11/21 Goldman Sachs
Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs
12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
ESPR Esperion
$31.29 /

+0.25 (+0.81%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
EXEL Exelixis
$24.13 /

+1.3 (+5.69%)

12/14/20 William Blair
Calithera risk/reward attractive into CANTATA readout, says William Blair
10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

01/06/21 BTIG
HealthEquity initiated with a Neutral at BTIG
01/06/21 Deutsche Bank
HealthEquity price target raised to $77 from $60 at Deutsche Bank
12/08/20 Cantor Fitzgerald
HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald
12/08/20 JPMorgan
HealthEquity price target raised to $72 from $61 at JPMorgan
MORF Morphic Holding
$29.83 /

-0.64 (-2.10%)

10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

09/15/20 Cantor Fitzgerald
Cantor reiterates $70 target on Nano-X after 'unfounded' short report
09/15/20 Cantor Fitzgerald
Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald
09/15/20 Oppenheimer
Nano-X Imaging initiated with a Perform at Oppenheimer
09/15/20 Berenberg
Nano-X Imaging initiated with a Buy at Berenberg
SRPT Sarepta
$89.78 /

+7.48 (+9.09%)

01/11/21
Fly Intel: Top five analyst downgrades
01/11/21 UBS
Sarepta downgraded to Neutral on 'unexpected negative' results at UBS
01/11/21 UBS
Sarepta downgraded to Neutral from Buy at UBS
01/08/21 Chardan
Solid Biosciences selloff on Sarepta news a buying opportunity, says Chardan
SHC Sotera Health
$25.59 /

+0.59 (+2.36%)

12/15/20 KeyBanc
Sotera Health initiated with an Overweight at KeyBanc
12/15/20 JPMorgan
Sotera Health initiated with an Overweight at JPMorgan
12/15/20 Jefferies
Sotera Health initiated with a Buy at Jefferies
12/15/20 Citi
Sotera Health initiated with a Buy at Citi
RVNC Revance
$29.00 /

-0.41 (-1.39%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
RUBY Rubius Therapeutics
$9.03 /

-0.47 (-4.95%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
ZYME Zymeworks
$56.48 /

-0.45 (-0.79%)

09/29/20 JPMorgan
Zymeworks resumed with a Neutral at JPMorgan
08/06/20
Fly Intel: Top analyst initiations
08/06/20 SVB Leerink
SVB Leerink bullish on Zymeworks, initiates with an Outperform
08/06/20 SVB Leerink
Zymeworks initiated with an Outperform at SVB Leerink
ZYME Zymeworks
$56.48 /

-0.45 (-0.79%)

SRPT Sarepta
$89.78 /

+7.48 (+9.09%)

SHC Sotera Health
$25.59 /

+0.59 (+2.36%)

RVNC Revance
$29.00 /

-0.41 (-1.39%)

RUBY Rubius Therapeutics
$9.03 /

-0.47 (-4.95%)

PCRX Pacira
$71.65 /

+1.58 (+2.25%)

NXGN NextGen Healthcare
$19.60 /

-0.26 (-1.31%)

NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

MORF Morphic Holding
$29.83 /

-0.64 (-2.10%)

HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

EXEL Exelixis
$24.13 /

+1.3 (+5.69%)

ESPR Esperion
$31.29 /

+0.25 (+0.81%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

AHCO AdaptHealth
$37.18 /

-1.06 (-2.77%)

AGIO Agios Pharmaceuticals
$46.71 /

+0.81 (+1.76%)

ABMD Abiomed
$324.31 /

+0.31 (+0.10%)

  • 06
    Jan
  • 15
    Dec
  • 16
    Dec
  • 19
    Nov
  • 20
    Nov
  • 03
    Sep
  • 21
    Aug
  • 09
    Jul
  • 01
    Jul
  • 12
    Feb
  • 23
    Jan
NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

SRPT Sarepta
$89.78 /

+7.48 (+9.09%)

RVNC Revance
$29.00 /

-0.41 (-1.39%)

OLMA Olema Oncology
$41.65 /

-0.84 (-1.98%)

NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

ESPR Esperion
$31.29 /

+0.25 (+0.81%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

BCAB BioAtla
$40.00 /

+1.79 (+4.68%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

NNOX Nano-X Imaging
$51.39 /

-1.625 (-3.07%)

HQY HealthEquity
$74.12 /

-1.03 (-1.37%)

ESPR Esperion
$31.29 /

+0.25 (+0.81%)

BIIB Biogen
$267.53 /

+15.17 (+6.01%)

AHCO AdaptHealth
$37.18 /

-1.06 (-2.77%)

Conference/Events
JPMorgan to hold a virtual conference » 09:44
01/11/21
01/11
09:44
01/11/21
09:44
ABMD

Abiomed

$324.00 /

+ (+0.00%)

, AGIO

Agios Pharmaceuticals

$45.85 /

-0.05 (-0.11%)

, AHCO

AdaptHealth

$38.24 /

+ (+0.00%)

, BCAB

BioAtla

$38.22 /

+0.01 (+0.03%)

, NXGN

NextGen Healthcare

$19.92 /

+0.06 (+0.30%)

, OLMA

Olema Oncology

$42.48 /

-0.01 (-0.02%)

, PCRX

Pacira

$70.03 /

-0.04 (-0.06%)

, BIIB

Biogen

$252.57 /

+0.21 (+0.08%)

, ESPR

Esperion

$31.04 /

+ (+0.00%)

, EXEL

Exelixis

$22.84 /

+0.01 (+0.04%)

, HQY

HealthEquity

$75.22 /

+0.07 (+0.09%)

, MORF

Morphic Holding

$30.47 /

+ (+0.00%)

, NNOX

Nano-X Imaging

$53.02 /

+ (+0.00%)

, SRPT

Sarepta

$82.30 /

+ (+0.00%)

, SHC

Sotera Health

$25.00 /

+ (+0.00%)

, RVNC

Revance

$29.41 /

+ (+0.00%)

, RUBY

Rubius Therapeutics

$9.50 /

+ (+0.00%)

, ZYME

Zymeworks

$56.95 /

+0.02 (+0.04%)

39th Annual Healthcare…

39th Annual Healthcare Virtual Conference will be held on January 11-14.

ShowHide Related Items >><<
ZYME Zymeworks
$56.95 /

+0.02 (+0.04%)

SRPT Sarepta
$82.30 /

+ (+0.00%)

SHC Sotera Health
$25.00 /

+ (+0.00%)

RVNC Revance
$29.41 /

+ (+0.00%)

RUBY Rubius Therapeutics
$9.50 /

+ (+0.00%)

PCRX Pacira
$70.03 /

-0.04 (-0.06%)

NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

MORF Morphic Holding
$30.47 /

+ (+0.00%)

HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

EXEL Exelixis
$22.84 /

+0.01 (+0.04%)

ESPR Esperion
$31.04 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

AHCO AdaptHealth
$38.24 /

+ (+0.00%)

AGIO Agios Pharmaceuticals
$45.85 /

-0.05 (-0.11%)

ABMD Abiomed
$324.00 /

+ (+0.00%)

ABMD Abiomed
$324.00 /

+ (+0.00%)

12/21/20 SVB Leerink
Abiomed price target raised to $320 from $280 at SVB Leerink
12/14/20 Piper Sandler
Abiomed gets approval for XR sheath, says Piper Sandler
10/20/20 Piper Sandler
Abiomed's TCT presentation highlights solid existing data, says Piper Sandler
08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
AGIO Agios Pharmaceuticals
$45.85 /

-0.05 (-0.11%)

12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
12/22/20 Barclays
Agios could enter 2022 with a third fewer shares, says Barclays
AHCO AdaptHealth
$38.24 /

+ (+0.00%)

01/07/21 Canaccord
AdaptHealth price target raised to $50 from $39 at Canaccord
12/10/20 UBS
AdaptHealth initiated with a Buy at UBS
12/04/20 Deutsche Bank
AdaptHealth price target raised to $47 from $36 at Deutsche Bank
12/02/20 SVB Leerink
AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink
BCAB BioAtla
$38.22 /

+0.01 (+0.03%)

01/11/21 Credit Suisse
BioAtla initiated with an Outperform at Credit Suisse
01/11/21 Jefferies
BioAtla initiated with a Buy at Jefferies
01/11/21 BTIG
BioAtla initiated with a Buy at BTIG
NXGN NextGen Healthcare
$19.92 /

+0.06 (+0.30%)

10/23/20 SVB Leerink
NextGen Healthcare price target raised to $14 from $12 at SVB Leerink
10/23/20 Piper Sandler
NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler
07/31/20 Piper Sandler
NextGen Healthcare price target raised to $23 from $17 at Piper Sandler
06/02/20 Deutsche Bank
NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank
OLMA Olema Oncology
$42.48 /

-0.01 (-0.02%)

12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
12/14/20 Canaccord
Olema Pharmaceuticals initiated with a Buy at Canaccord
12/14/20 Cowen
Olema Pharmaceuticals initiated with an Outperform at Cowen
PCRX Pacira
$70.03 /

-0.04 (-0.06%)

01/06/21 RBC Capital
Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas
12/14/20 Barclays
Pacira price target raised to $79 from $73 at Barclays
09/30/20 Jefferies
Pacira price target raised to $75 from $69 at Jefferies
09/21/20 Northland
Pacira upgraded to Outperform on Exparel sales expectations at Northland
BIIB Biogen
$252.57 /

+0.21 (+0.08%)

12/04/20 Mizuho
Sage Therapeutics upgraded to Buy from Neutral at Mizuho
12/01/20 Truist
Sage Therapeutics price target raised to $70 from $60 at Truist
12/01/20 Raymond James
Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James
12/01/20 Citi
Sage Therapeutics price target lowered to $93 from $100 at Citi
ESPR Esperion
$31.04 /

+ (+0.00%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
EXEL Exelixis
$22.84 /

+0.01 (+0.04%)

12/14/20 William Blair
Calithera risk/reward attractive into CANTATA readout, says William Blair
10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

01/06/21 BTIG
HealthEquity initiated with a Neutral at BTIG
01/06/21 Deutsche Bank
HealthEquity price target raised to $77 from $60 at Deutsche Bank
12/08/20 Cantor Fitzgerald
HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald
12/08/20 JPMorgan
HealthEquity price target raised to $72 from $61 at JPMorgan
MORF Morphic Holding
$30.47 /

+ (+0.00%)

10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital
NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

09/15/20 Cantor Fitzgerald
Cantor reiterates $70 target on Nano-X after 'unfounded' short report
09/15/20 Cantor Fitzgerald
Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald
09/15/20 Oppenheimer
Nano-X Imaging initiated with a Perform at Oppenheimer
09/15/20 Berenberg
Nano-X Imaging initiated with a Buy at Berenberg
SRPT Sarepta
$82.30 /

+ (+0.00%)

01/11/21 UBS
Sarepta downgraded to Neutral on 'unexpected negative' results at UBS
01/11/21 UBS
Sarepta downgraded to Neutral from Buy at UBS
01/08/21 Chardan
Solid Biosciences selloff on Sarepta news a buying opportunity, says Chardan
01/08/21 JPMorgan
Sarepta downgraded to Underweight from Overweight at JPMorgan
SHC Sotera Health
$25.00 /

+ (+0.00%)

12/15/20 KeyBanc
Sotera Health initiated with an Overweight at KeyBanc
12/15/20 JPMorgan
Sotera Health initiated with an Overweight at JPMorgan
12/15/20 Jefferies
Sotera Health initiated with a Buy at Jefferies
12/15/20 Citi
Sotera Health initiated with a Buy at Citi
RVNC Revance
$29.41 /

+ (+0.00%)

12/29/20 Needham
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List
11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
RUBY Rubius Therapeutics
$9.50 /

+ (+0.00%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
ZYME Zymeworks
$56.95 /

+0.02 (+0.04%)

09/29/20 JPMorgan
Zymeworks resumed with a Neutral at JPMorgan
08/06/20
Fly Intel: Top analyst initiations
08/06/20 SVB Leerink
SVB Leerink bullish on Zymeworks, initiates with an Outperform
08/06/20 SVB Leerink
Zymeworks initiated with an Outperform at SVB Leerink
ZYME Zymeworks
$56.95 /

+0.02 (+0.04%)

SRPT Sarepta
$82.30 /

+ (+0.00%)

SHC Sotera Health
$25.00 /

+ (+0.00%)

RVNC Revance
$29.41 /

+ (+0.00%)

RUBY Rubius Therapeutics
$9.50 /

+ (+0.00%)

PCRX Pacira
$70.03 /

-0.04 (-0.06%)

NXGN NextGen Healthcare
$19.92 /

+0.06 (+0.30%)

NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

MORF Morphic Holding
$30.47 /

+ (+0.00%)

HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

EXEL Exelixis
$22.84 /

+0.01 (+0.04%)

ESPR Esperion
$31.04 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

AHCO AdaptHealth
$38.24 /

+ (+0.00%)

AGIO Agios Pharmaceuticals
$45.85 /

-0.05 (-0.11%)

ABMD Abiomed
$324.00 /

+ (+0.00%)

  • 06
    Jan
  • 15
    Dec
  • 16
    Dec
  • 19
    Nov
  • 20
    Nov
  • 03
    Sep
  • 21
    Aug
  • 09
    Jul
  • 01
    Jul
  • 12
    Feb
  • 23
    Jan
NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

SRPT Sarepta
$82.30 /

+ (+0.00%)

RVNC Revance
$29.41 /

+ (+0.00%)

OLMA Olema Oncology
$42.48 /

-0.01 (-0.02%)

NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

ESPR Esperion
$31.04 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

BCAB BioAtla
$38.22 /

+0.01 (+0.03%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

NNOX Nano-X Imaging
$53.02 /

+ (+0.00%)

HQY HealthEquity
$75.22 /

+0.07 (+0.09%)

ESPR Esperion
$31.04 /

+ (+0.00%)

BIIB Biogen
$252.57 /

+0.21 (+0.08%)

AHCO AdaptHealth
$38.24 /

+ (+0.00%)

Recommendations
Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List » 07:35
12/29/20
12/29
07:35
12/29/20
07:35
COLL

Collegium Pharmaceutical

$18.94 /

+0.45 (+2.43%)

, RVNC

Revance

$27.88 /

+0.26 (+0.94%)

Needham analyst Serge…

Needham analyst Serge Belanger named Collegium Pharmaceutical (COLL) as his 2021 best idea and added the company to Needham Conviction List in place of Revance Therapeutics (RVNC), which was removed. The analyst is also keeping his Buy rating and $34 price target on Collegium. Belanger states that the growth prospects of the company's Xtampza within the "complex" opioid market remains its "key value driver" with significant sales growth expected next year, but the investment story has grown to include its "stabilized" Nucynta franchise. The analyst believes that Nucynta could contribute to Collegium's top-line growth and a "leverageable" cost structure that will further improve the company's profitability and cash generation.

ShowHide Related Items >><<
RVNC Revance
$27.88 /

+0.26 (+0.94%)

COLL Collegium Pharmaceutical
$18.94 /

+0.45 (+2.43%)

COLL Collegium Pharmaceutical
$18.94 /

+0.45 (+2.43%)

07/14/20 BWS Financial
Collegium Pharmaceutical initiated with a Sell at BWS Financial
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Collegium Pharmaceutical initiated with a Neutral at Guggenheim
03/23/20 Truist
SunTrust lowers price targets among Pharmaceuticals due to COVID-19
RVNC Revance
$27.88 /

+0.26 (+0.94%)

11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
10/15/20 H.C. Wainwright
Revance price target raised to $33 from $27 at H.C. Wainwright
RVNC Revance
$27.88 /

+0.26 (+0.94%)

COLL Collegium Pharmaceutical
$18.94 /

+0.45 (+2.43%)

RVNC Revance
$27.88 /

+0.26 (+0.94%)

Over a month ago
Hot Stocks
Revance and Ajinomoto announce strategic commercial manufacturing agreement » 08:06
12/22/20
12/22
08:06
12/22/20
08:06
RVNC

Revance

$27.03 /

+0.265 (+0.99%)

Ajinomoto Bio-Pharma…

Ajinomoto Bio-Pharma Services and Revance Therapeutics announced a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review. Aji Bio-Pharma will serve as a dual supply source and provide drug product manufacturing services for Revance at the company's aseptic manufacturing facility in San Diego, California.

ShowHide Related Items >><<
RVNC Revance
$27.03 /

+0.265 (+0.99%)

RVNC Revance
$27.03 /

+0.265 (+0.99%)

11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
10/15/20 H.C. Wainwright
Revance price target raised to $33 from $27 at H.C. Wainwright
RVNC Revance
$27.03 /

+0.265 (+0.99%)

RVNC Revance
$27.03 /

+0.265 (+0.99%)

Hot Stocks
Revance announces topline results from DaxibotulinumtoxinA trial » 08:28
12/17/20
12/17
08:28
12/17/20
08:28
RVNC

Revance

$26.59 /

-0.17 (-0.64%)

Revance announced topline…

Revance announced topline efficacy and safety results from its Phase 2 multicenter, open-label study of investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, which are comprised of glabellar lines, or GL, dynamic forehead lines, or FHL, and lateral canthal lines, or LCL, commonly known as crow's feet lines. In the Phase 2 study, 48 subjects were enrolled to receive a single treatment of DaxibotulinumtoxinA for Injection with a total study duration of 36 weeks. Subjects received 40, 32, and 48 units of DaxibotulinumtoxinA for Injection respectively in the glabellar complex, forehead and lateral canthal areas. The key endpoints for efficacy were the proportion of subjects achieving a score of none or mild wrinkle severity at maximum contraction at Week 4, as assessed on the Investigator Global Assessment Frown Wrinkle Severity, or IGA-FWS, Investigator Global Assessment Forehead Wrinkle Severity, or IGA-FHWS and Investigator Global Assessment Lateral Canthal Wrinkle Severity, or IGA-LCWS, respectively. The study measured duration of effect in responders.These duration measures were defined as the median time to return to baseline wrinkle severity or the time to loss of none or mild wrinkle severity, both based on investigator and subject assessments. DaxibotulinumtoxinA for Injection was generally safe and well tolerated when all three facial areas were injected simultaneously. There were no treatment-related serious adverse events, or SAEs. The most common adverse events, or AEs, were injection site erythema, facial discomfort and headache. No eyelid or brow ptosis was reported. Participants used a 7-point Subject Global Satisfaction with Treatment Questionnaire to rate their satisfaction with treatment of DaxibotulinumtoxinA for Injection. At Week 4, 100% of participants reported being at least "Somewhat Satisfied" with the treatment in all three areas, and 83%, 78.7%, and 80.9% reported being "Very Satisfied" with the treatment of their glabellar lines, forehead lines, and crow's feet, respectively.

ShowHide Related Items >><<
RVNC Revance
$26.59 /

-0.17 (-0.64%)

RVNC Revance
$26.59 /

-0.17 (-0.64%)

11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
10/15/20 H.C. Wainwright
Revance price target raised to $33 from $27 at H.C. Wainwright
RVNC Revance
$26.59 /

-0.17 (-0.64%)

RVNC Revance
$26.59 /

-0.17 (-0.64%)

Hot Stocks
Revance to relocate headquarters from Silicon Valley to Nashville » 08:46
12/16/20
12/16
08:46
12/16/20
08:46
RVNC

Revance

$26.76 /

+0.24 (+0.90%)

Tennessee Gov. Bill Lee,…

Tennessee Gov. Bill Lee, Department of Economic and Community Development Commissioner Bob Rolfe and Revance Therapeutics officials announced that the company will relocate its headquarters from Silicon Valley's Newark, California, to Nashville, Tennessee.

ShowHide Related Items >><<
RVNC Revance
$26.76 /

+0.24 (+0.90%)

RVNC Revance
$26.76 /

+0.24 (+0.90%)

11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
10/15/20 H.C. Wainwright
Revance price target raised to $33 from $27 at H.C. Wainwright
RVNC Revance
$26.76 /

+0.24 (+0.90%)

RVNC Revance
$26.76 /

+0.24 (+0.90%)

Conference/Events
Revance management to meet virtually with Mizuho » 04:55
12/07/20
12/07
04:55
12/07/20
04:55
RVNC

Revance

$24.34 /

+0.35 (+1.46%)

Virtual Meeting to be…

Virtual Meeting to be held on December 7 hosted by Mizuho.

ShowHide Related Items >><<
RVNC Revance
$24.34 /

+0.35 (+1.46%)

RVNC Revance
$24.34 /

+0.35 (+1.46%)

11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
10/15/20 H.C. Wainwright
Revance price target raised to $33 from $27 at H.C. Wainwright
RVNC Revance
$24.34 /

+0.35 (+1.46%)

RVNC Revance
$24.34 /

+0.35 (+1.46%)

Conference/Events
Revance management to meet virtually with Mizuho » 14:04
12/04/20
12/04
14:04
12/04/20
14:04
RVNC

Revance

$24.17 /

+0.18 (+0.75%)

Virtual Meeting to be…

Virtual Meeting to be held on December 7 hosted by Mizuho.

ShowHide Related Items >><<
RVNC Revance
$24.17 /

+0.18 (+0.75%)

RVNC Revance
$24.17 /

+0.18 (+0.75%)

11/25/20 H.C. Wainwright
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
11/10/20 Mizuho
Revance price target lowered to $30 from $32 at Mizuho
10/26/20 Barclays
Revance price target raised to $38 from $35 at Barclays
10/15/20 H.C. Wainwright
Revance price target raised to $33 from $27 at H.C. Wainwright
RVNC Revance
$24.17 /

+0.18 (+0.75%)

RVNC Revance
$24.17 /

+0.18 (+0.75%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.